oxfendazole profile

Oxfendazole is a benzimidazole anthelmintic drug used to treat a variety of internal and external parasitic infections in animals. It acts by inhibiting the synthesis of tubulin, a protein essential for the formation of microtubules, which are crucial for cell division and other cellular processes in parasites. Oxfendazole has a broad spectrum of activity against various parasites, including nematodes, cestodes, and trematodes. It is commonly used in veterinary medicine to treat infections in livestock, poultry, and companion animals. The compound is typically administered orally, either in tablet or liquid form. Its effectiveness is influenced by factors such as the type of parasite, the animal species, and the dosage regimen.'

ID Source	ID
PubMed CID	40854
CHEMBL ID	42442
CHEBI ID	35812
SCHEMBL ID	44121
SCHEMBL ID	9818561
MeSH ID	M0057032

Synonym
AKOS005448898
AB01275512-01
BRD-A33447119-001-02-5
5-phenylsulfinyl-2-carbomethoxyaminobenzimidazole
5-(phenylsulfinyl)-2-benzimidazolecarbamic acid methyl ester
methyl [5-(phenylsulfinyl)-1h-benzimidazol-2-yl]carbamate
CHEBI:35812 ,
fenbendazole s-oxide
fenbendazole sulfoxide
(5-(phenylsulfinyl)-1h-benzimidazol-2-yl)carbamic acid methyl ester
ofdz
oxfendazole [usan:ban:inn]
2-benzimidazolecarbamic acid, 5-(phenylsulfinyl)-, methyl ester
methyl 5(6)-phenylsulfinyl-2-benzimidazolecarbamate
oxfendazol [inn-spanish]
brn 0761290
hoe 8105
synanthic
carbamic acid, 5-(phenylsulfinyl)-1h-benzimidazol-2-yl-, methyl ester
systemax
oxfendazolum [inn-latin]
rs 8858
methyl (5-phenylsulfinyl)-1h-benzimidazol-2-yl carbamate
synanthic (veterinary)
carbamic acid, (5-(phenylsulfinyl)-1h-benzimidazol-2-yl)-, methyl ester
methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate
systamex
repidose
einecs 258-714-5
OPREA1_563224
fbz-so
53716-50-0
[5-(phenylsulfinyl)-1h-benzimidazol-2-yl]carbamic acid methyl ester
methyl n-[5-(benzenesulfinyl)-1h-benzimidazol-2-yl]carbamate
oxfendazole ,
D05291
synanthic [veterinary] (tn)
oxfendazole (usp/inn)
BSPBIO_003572
rs-8858
NCGC00095157-01
NCGC00095157-02
KBIO3_002947
SPECTRUM3_001972
SPBIO_001688
SPECTRUM2_001704
SPECTRUM1505296
NCGC00095157-03
STK378905
HMS2090F19
HMS2093O16
CHEMBL42442 ,
nsc-758943
methyl n-[6-(benzenesulfinyl)-1h-benzimidazol-2-yl]carbamate
HMS1922B08
bdbm50300124
NCGC00095157-04
cas-53716-50-0
dtxsid9044112 ,
NCGC00255714-01
dtxcid7024112
tox21_302383
tox21_113444
n-[6-(benzenesulfinyl)-1h-benzimidazol-2-yl]carbamic acid methyl ester
A829749
methyl n-[6-(phenylsulfinyl)-1h-benzimidazol-2-yl]carbamate
nsc758943
pharmakon1600-01505296
methyl [5-(phenylsulfinyl)benzimidazol-2-yl]carbamate
[5-(phenylsulfinyl)benzimidazol-2-yl]carbamic acid methyl ester
O0391
MLS004712073
smr001550468
AKOS015918230
CCG-39503
nsc 758943
unii-omp2h17f9e
omp2h17f9e ,
ccris 9430
oxfendazole [usan:usp:inn:ban]
oxfendazolum
oxfendazol
methyl 5-(phenylsulfinyl)-benzimidazol-2-carbamate
FT-0630662
NCGC00095157-06
oxfendazole [usp monograph]
oxfendazole [usan]
oxfendazole [green book]
oxfendazole [inn]
oxfendazole [usp-rs]
oxfendazole [mi]
oxfendazole [mart.]
S1830
CCG-220984
HY-B0291
SCHEMBL44121
NCGC00095157-05
tox21_113444_1
KS-5036
SCHEMBL9818561
Q-201525
BEZZFPOZAYTVHN-UHFFFAOYSA-N
carbamic acid, n-[6-(phenylsulfinyl)-1h-benzimidazol-2-yl]-, methyl ester
AB01275512_03
AB01275512_02
methyl n-[5-(benzenesulfinyl)-1h-1,3-benzodiazol-2-yl]carbamate
methyl 6-(phenylsulfinyl)-1h-benzimidazol-2-ylcarbamate
carbamic acid, [5-(phenylsulfinyl)-1h-benzimidazol-2-yl]-, methyl ester
AC-8715
SR-01000872713-1
sr-01000872713
methyl (6-(phenylsulfinyl)-1h-benzo[d]imidazol-2-yl)carbamate
oxfendazole, vetranal(tm), analytical standard
oxfendazole, united states pharmacopeia (usp) reference standard
HMS3655M14
oxfendazole, european pharmacopoeia (ep) reference standard
oxfendazole (fenbendazole sulfoxide)
fenbendazole sulphoxide; oxfendazole; fenbendazole sulfoxide
fenbendazole sulphoxide (oxfendazole)
nanthic
synanthic (tn)
methyl [5-(phenylsulfinyl)-1h-benzimidazol-2-yl]carbamate, 9ci
benzelmin
SBI-0206760.P001
HMS3715E09
SW199450-2
methyl 6-(phenylsulfinyl)-1h-benzo[d]imidazol-2-ylcarbamate
fenbendazole sulphoxide
DB11446
mfcd00801063
oxfendazole 100 microg/ml in acetonitrile
BCP09602
C21882
Q7115199
BRD-A33447119-001-05-8
BRD-A33447119-001-03-3
methyl 5-(phenylsulfinyl)-1h-benzo[d]imidazol-2-ylcarbamate
A905222
T72586
oxfendazole-d3(fenbendazole sulfoxide-d3)
carbamic acid, n-[5-(phenylsulfinyl)-1h-benzimidazol-2-yl]-, methyl ester
benzelmin top dress.
benzelmin equine anthelmintic suspension, synanthic suspension
oxfendazol (inn-spanish)
oxfendazole (mart.)
methyl (5-(phenylsulfinyl)-1h-benzimidazol-2-yl)carbamate
synanthic bovine dewormer suspension 22.5%, synanthic bovine dewormer suspension 9.06%
benzelmin powder for suspension
synanthic bovine dewormer
benzelmin equine anthelmic paste, synanthic oral paste
oxfendazole (usan:usp:inn:ban)
oxfendazole (usp monograph)
oxfendazole (usp-rs)
synanthic bovine dewormer paste, 18.5%
oxfendazolum (inn-latin)
SY052761
methyl [6-(phenylsulfinyl)-2-benzimidazolyl]carbamate

Research Excerpts

Overview

Oxfendazole (OXF) is a potent veterinary benzimidazole anthelmintic under transition to humans for the treatment of multiple parasitic infectious diseases. It was shown to be a very potent agent in killing Trichinella spiralis.

Excerpt	Reference	Relevance
"Oxfendazole is a potent veterinary antiparasitic drug undergoing development for human use to treat multiple parasitic infections. "	( Population Pharmacokinetic-Pharmacodynamic Model of Oxfendazole in Healthy Adults in a Multiple Ascending Dose and Food Effect Study and Target Attainment Analysis. An, G; Bach, T; Codd, EE; Deye, GA; Horton, J; Winokur, P, 2022)	2.41
"Oxfendazole (OXF) is an albendazole derivative with efficacy against tissue cestodes of veterinary importance."	( Oxfendazole induces protein catabolism and gluconeogenesis in experimental neurocysticercosis. Correia, LTB; Costa, TL; de Lima, NF; De Sousa Guerra, CH; Gomes, TC; Vinaud, MC, 2022)	2.89
"Oxfendazole is a potent veterinary benzimidazole anthelmintic under transition to humans for the treatment of multiple parasitic infectious diseases. "	( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021)	2.34
"Oxfendazole was shown to be a very potent agent in killing Trichinella spiralis. "	( A comparison of the anthelmintic effects of oxfendazole and oxibendazole on Trichinella spiralis in mice. Denham, DA; Karunakaran, CS, 1980)	1.97

Effects

Oxfendazole has been shown to be highly effective against porcine cysticercosis, when given as a single dose at 30 mg/kg bodyweight. Oxf endazole therefore has potential to be efficacious for treatment of human filariasis without causing adverse reactions due to drug-induced microfilariae killing.

Excerpt	Reference	Relevance
"Oxfendazole therefore has potential to be efficacious for treatment of human filariasis without causing adverse reactions due to drug-induced microfilariae killing."	( Oxfendazole mediates macrofilaricidal efficacy against the filarial nematode Litomosoides sigmodontis in vivo and inhibits Onchocerca spec. motility in vitro. Dubben, B; Ehrens, A; Fendler, M; Frohberger, SJ; Gokool, S; Hoerauf, A; Hübner, MP; Koschel, M; Lustigman, S; Martin, C; Mitre, E; Scandale, I; Schneider, M; Specht, S; Struever, D; Townson, S; Vallarino-Lhermitte, N, 2020)	2.72
"Oxfendazole has been shown to be highly effective against porcine cysticercosis, when given as a single dose at 30 mg/kg bodyweight."	( Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Bernal, T; Falcon, N; Garcia, HH; Gavidia, C; Gilman, RH; Gonzalez, AE; Romero, M; Tsang, VC, 1997)	1.29

Treatment

Treatment with oxfendazole confirmed the benzimidazole-resistance status of the two species. Ewes treated with ox fendazoles had a significantly lower egg output than those treated with levamisole.

Excerpt	Reference	Relevance
"Treatment with oxfendazole alone or oxfendazole plus praziquantel killed all of the parasites, and left only microcalcifications in the meat."	( Effective, single-dose treatment or porcine cysticercosis with oxfendazole. Bernal, T; Falcon, N; Garcia, HH; Gavidia, CM; Gilman, RH; Gonzales, AE; Lopez-Urbina, MT; Romero, M; Tsang, VC, 1996)	0.87
"Treatment with oxfendazole confirmed the benzimidazole-resistance status of the two species."	( The efficacy of levamisole, and a mixture of oxfendazole and levamisole, against the arrested stages of benzimidazole-resistant Haemonchus contortus and Ostertagia circumcincta in sheep. Andrews, SJ, 2000)	0.91
"Ewes treated with oxfendazole had a significantly lower egg output than those treated with levamisole, although the latter anthelmintic was also highly effective."	( Controlled trials of the anthelmintic oxfendazole in ewes and lambs naturally infected with gastrointestinal nematodes. Downey, NE, 1977)	0.85

Toxicity

Excerpt	Reference	Relevance
"The possible correlations between embryotoxicity, plasma kinetics of toxic metabolites and covalent binding of metabolites to foetal tissues were studied using two drugs, albendazole and oxfendazole."	( A correlation of toxicity of albendazole and oxfendazole with their free metabolites and bound residues. Benoit, E; Delatour, P; Garnier, F; Longin, C, 1984)	0.72
" The no observed adverse effect level was determined to be >5 but <25 mg/kg/d and the maximum tolerated dose 100 mg/kg/d."	( Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies. Codd, EE; Doppalapudi, R; Garcia, HH; Gilman, RH; Gonzalez, AE; Horton, RJ; McFarlane, C; Mirsalis, JC; Ng, HH; Riccio, ES, )	0.36

Pharmacokinetics

Oxfendazole (OFZ) administration resulted in the peak plasma OFZ concentration occurring sooner. The area under the plasma OfZ concentration curve was reduced when compared with intraruminal administration. A population pharmacokinetic model was developed using a nonlinear mixed-effect modeling approach.

Excerpt	Reference	Relevance
" It did increase the tmax to 16."	( Pharmacokinetics of fenbendazole in dogs. Galbraith, EA; Harrison, P; Inglis, H; McKellar, QA, 1990)	0.28
"Direct intraabomasal oxfendazole (OFZ) administration resulted in the peak plasma OFZ concentration occurring sooner and the area under the plasma OFZ concentration curve being reduced when compared with intraruminal administration."	( Effect of oesophageal groove closure on the pharmacokinetic behaviour and efficacy of oxfendazole in sheep. Hennessy, DR; Prichard, RK, 1981)	0.8
"Oxfendazole, fenbendazole and albendazole were each administered at 5mgkg(-1) to sheep fitted with abomasal cannulae as a single bolus intra-ruminally or infused intra-abomasally at a declining exponential rate, with half-life equivalent to the rate of rumen fluid outflow."	( Influence of ruminal bypass on the pharmacokinetics and efficacy of benzimidazole anthelmintics in sheep. Hennessy, DR; Steel, JW, 1999)	1.75
" Achiral and chiral pharmacokinetic (PK) profiles for OFZ, after the co-administration of PB, were characterized by a significantly greater area under the concentration--time curve (AUC) and a longer mean residence time (MRT)."	( Plasma achiral and chiral pharmacokinetic behaviour of intravenous oxfendazole co-administered with piperonyl butoxide in sheep. Jones, DG; McKellar, QA; Sánchez, S; Small, J, 2002)	0.55
" This work examines the mechanism involved in intestinal elimination of ABZSO and their pharmacokinetic consequences in rat and sheep."	( Intestinal elimination of albendazole sulfoxide: pharmacokinetic effects of inhibitors. Alvarez, AI; García, JL; Merino, G; Molina, AJ; Prieto, JG; Pulido, MM, 2003)	0.32
"This study compared pharmacokinetic (PK) profiles in sheep dosed intravenously with three different concentrations of oxfendazole (OFZ)."	( Effects of formulation concentration on intravenous pharmacokinetics, chirality and in vitro solubility of oxfendazole and its metabolites in sheep. Jones, DG; McKellar, QA; Sánchez Bruni, SF; Small, J, 2005)	0.75
" Additionally, the comparative pharmacokinetic behaviour of FLBZ (and its metabolites) administered by the intraruminal (i."	( Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution. Alvarez, L; Ceballos, L; Lanusse, C; Moreno, L; Torrado, JJ, 2012)	0.38
" However, oppositely to what was expected, the absorption-related pharmacokinetic parameters did not show any marked formulation-dependant effect."	( Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution. Alvarez, L; Ceballos, L; Lanusse, C; Moreno, L; Torrado, JJ, 2012)	0.38
" The assessment of the OFZ and metabolites [(fenbendazole sulphone (FBZSO2), fenbendazole (FBZ)] plasma pharmacokinetic and tissue residue profiles after its oral administration to pigs and the withdrawal period for human consumption were reported."	( A high oxfendazole dose to control porcine cysticercosis: pharmacokinetics and tissue residue profiles. Domingue, G; Donadeu, M; Dungu, B; Farias, C; García, HH; Gomez-Puerta, LA; González, AE; Lanusse, C; Lopez-Urbina, MT; Moreno, L, 2012)	0.83
" Within-drug and metabolite analysis of pharmacokinetic parameters included fixed effects of drug administration date, sex and breed of sire."	( The effect of breed and sex on sulfamethazine, enrofloxacin, fenbendazole and flunixin meglumine pharmacokinetic parameters in swine. Ashwell, MS; Baynes, RE; Bellis, B; Brooks, JD; Howard, JT; Maltecca, C; O'Nan, AT; Routh, P; Yeatts, JL, 2014)	0.4
"The most popular standard treatments for soil transmitted helminths in humans including mebendazole, albendazole, levamisole, and pyrantel pamoate, show greatly variable efficacy against different species of parasites and have unfavorable pharmacokinetic characteristics, such as short half-life."	( Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study. An, G; Bach, T; Bae, S; D'Cunha, R; Winokur, P, 2019)	0.73
" To quantitatively capture the relation between oxfendazole dose and exposure, a population pharmacokinetic model for oxfendazole and its metabolites, oxfendazole sulfone and fenbendazole, in humans was developed using a nonlinear mixed-effect modeling approach."	( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021)	1.15
" In this study, we compared the performance of FOCE, FOCE FAST, and two EM methods, namely importance sampling (IMP) and stochastic approximation expectation-maximization (SAEM), utilizing the rich pharmacokinetic data of oxfendazole and its two metabolites obtained from the first-in-human single ascending dose study in healthy adults."	( Comparing the performance of first-order conditional estimation (FOCE) and different expectation-maximization (EM) methods in NONMEM: real data experience with complex nonlinear parent-metabolite pharmacokinetic model. An, G; Bach, T, 2021)	0.81

Bioavailability

The resultant increase in bioavailability of FBZ and its metabolite oxfendazole has important implications for the efficacy of these drugs against benzimidazole (BZD)-resistant strains of Teladorsagia circumcincta.

Excerpt	Reference	Relevance
" The bioavailability of OFZ after oral administration was lower in goats than in sheep."	( Pharmacokinetics of oxfendazole in goats: a comparison with sheep. Benoit, E; Bogan, J; Delatour, P, 1987)	0.6
" A comparative bioavailability study of these 3 suspensions was performed in 12 sheep with each sheep given each formulation in a Latin square crossover study design; oxfendazole was dosed at rate of 5 mg/kg of body weight."	( Relationship among particle size distribution, dissolution profile, plasma values, and anthelmintic efficacy of oxfendazole. Hennessey, DR; Mroszczak, E; Nguyen, TH; Parekh, P; Prichard, RK; Schiltz, R; Shastri, S, 1980)	0.67
" Administration of fenbendazole at a dose rate of 20 mg/kg in food, irrespective of fat content, did however significantly increase its bioavailability when compared to administration of the same dose as a bolus on an empty stomach."	( Oral absorption and bioavailability of fenbendazole in the dog and the effect of concurrent ingestion of food. Baxter, P; Galbraith, EA; McKellar, QA, 1993)	0.29
"In the present study the bioavailability of febantel paste and febantel suspension was investigated in the fully hydrated and the dehydrated camel."	( The bioavailability of febantel in dehydrated camels. Ben-Zvi, Z; Gussarsky, E; van Creveld, C; Yagil, R, 1996)	0.29
" Bioavailability of fenbendazole was 27."	( Pharmacokinetics of fenbendazole following intravenous and oral administration to pigs. Friis, C; Petersen, MB, 2000)	0.31
" The drug was rapidly absorbed after oral administration, but systemic bioavailability was low."	( Pharmacokinetics of fenbendazole following intravenous and oral administration to pigs. Friis, C; Petersen, MB, 2000)	0.31
" The resultant increase in bioavailability of FBZ and its metabolite oxfendazole (OFZ) has important implications for the efficacy of these drugs against benzimidazole (BZD)-resistant strains of Teladorsagia circumcincta."	( Plasma achiral and chiral pharmacokinetic behaviour of intravenous oxfendazole co-administered with piperonyl butoxide in sheep. Jones, DG; McKellar, QA; Sánchez, S; Small, J, 2002)	0.79
" These ABC drug efflux transporters extrude a wide range of xenotoxins from cells in intestine, liver, and other organs, thus affecting the bioavailability of many compounds."	( Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2). Alvarez, AI; Jonker, JW; Merino, G; Molina, AJ; Pulido, MM; Schinkel, AH; Wagenaar, E, 2005)	0.33
" A higher metabolic capacity, first-pass effects and lower absorption of benzimidazoles in donkeys decrease bioavailability and efficacy compared to ruminants."	( Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys. Akar, F; Gokbulut, C; McKellar, QA, 2006)	0.6
" More recent work has expanded oxfendazole's nonclinical safety profile and demonstrated its safety and bioavailability in healthy human volunteers, thus advancing the possibility of a new and greatly needed option for antiparasitic treatment of geohelminths and tissue parasites."	( Oxfendazole: a promising agent for the treatment and control of helminth infections in humans. Codd, EE; Garcia, HH; Gilman, RH; Gonzalez, AE; Horton, J, 2019)	2.24
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
" Our final model incorporated mechanistic characterization of dose-limited bioavailability as well as different oxfendazole metabolic processes and provided insight into the significance of presystemic metabolism in oxfendazole and metabolite disposition."	( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021)	1.11

Dosage Studied

The efficacy of oxfendazole was tested in naturally infected Sokoto-Gudali calves at a dosage of 2 mg/kg. A comparative bioavailability study of these 3 suspensions was performed in 12 sheep. The assay has been used for statutory testing purposes.

Excerpt	Relevance	Reference
" At both dosage levels, oxfendazole was 100% effective against third, fourth, early fifth, and adult stages of the worms."	( Efficacy of oxfendazole against an ovine isolate of benzimidazole resistant Haemonchus contortus. Kistner, TP; Wyse, D, 1978)	0.94
" Two-week posttreatment mean strongyle epg and lpg (small strongyle) values for barn-E horses, treated alternately with therapeutic (approx) dosage of IVE (200 micrograms/kg; 4 times), OFZ (10 mg/kg; 5 times), OBZ (10 mg/kg; 4 times), or PRT (6."	( Evaluation of exclusive use of ivermectin vs alternation of antiparasitic compounds for control of internal parasites of horses. Drudge, JH; Granstrom, DE; Lyons, ET; Stamper, S; Tolliver, SC, 1992)	0.28
"5 mg kg-1), cows being dosed from calving and calves starting 45 days later."	( Epidemiology and effects of nematode infections on beef cow-calf systems of Argentina's western pampas. Busetti, MR; Fort, MC; Suarez, VH, 1992)	0.28
" Thiabendazole at a dosage of 44 mg/kg was tested in 8 foals, oxfendazole at 10 mg/kg was tested in 4 foals, and phenothiazine at 55 mg/kg, cambendazole at 20 mg/kg, and fenbendazole at 5 mg/kg were tested in 1 foal each."	( Resistance of population-B equine strongyles to thiabendazole, oxfendazole, and phenothiazine (1981 to 1987). Drudge, JH; Lyons, ET; Tolliver, SC, 1991)	0.76
"When they were turned out to grass in May 1987 for their first season, 10 calves were dosed with a 5 x 750 mg oxfendazole pulse release bolus (OPRB) and a monensin sodium rumen delivery device (RDD); eight calves received one OPRB; 10 calves received one RDD and eight calves received neither bolus."	( Concurrent use of the oxfendazole pulse release bolus and the monensin rumen delivery device in young grazing cattle. McEvoy, CM; Rowlands, DT; Woollon, RM, 1989)	0.8
"One group of first-season calves was dosed with an oxfendazole pulse release bolus at spring turnout (April 30) and on July 15 a second group received the front-loaded oxfendazole pulse release bolus."	( Pasture study of two types of oxfendazole pulse release bolus for controlling nematodes in calves. Downey, NE, 1988)	0.82
" Each of the animals in groups 1 and 4 was dosed with an oxfendazole pulse release bolus at turn out whereas the animals in groups 2 and 3 were left untreated."	( Control of naturally acquired bovine parasitic bronchitis and gastroenteritis with an oxfendazole pulse release device. Armour, J; Bairden, K; Oakley, GA; Rowlands, DT, 1988)	0.74
" One group was dosed at turnout with the OPRB, the second group with the MSRB and the third group left as nontreated controls."	( Control of gastrointestinal parasitism with an oxfendazole pulse-release anthelmintic device. Bell, SL; Thomas, RJ, 1988)	0.53
"Oxfendazole paste formulation was administered intraorally at a dosage of 10 mg/kg of body weight, twice (48 hours between treatments) in 5 controlled tests (experiments A, B, C, D, and E) to 18 equids (14 horses and 4 ponies) that were 5 to 24 months old in 1986 and 1987."	( Oxfendazole: activity of a two-dose treatment regimen on natural infections of internal parasites of equids, with emphasis on migrating large strongyles in controlled tests in 1986 and 1987. Drudge, JH; Lyons, ET; Swerczek, TW; Tolliver, SC, 1988)	3.16
" At turn-out each calf in the group of 40 calves was dosed orally with a pulsed release bolus designed to deliver five doses of oxfendazole at regular intervals during a period of up to 130 days, the first dose being released about 21 days after administration."	( Assessment of an oxfendazole pulsed release bolus for control of parasitic gastroenteritis in calves in a rotational grazing system. Mitchell, GB, 1987)	0.82
" No signs of clinical disease were observed in either the animals dosed with a pulse release bolus or the undosed control animals during the two year trial period."	( Use of an oxfendazole pulse release bolus in calves exposed to natural subclinical infection with gastrointestinal nematodes. Herbert, IV; Probert, AJ, 1987)	0.68
" One week after inoculation, 1 group of 4 foals was given oxfendazole (OFZ) at a dosage rate of 10 mg/kg of body weight, another group was given 2 such treatments 48 hours apart, and a 3rd group was given a placebo."	( Effectiveness of oxfendazole against early and later 4th-stage Strongylus vulgaris in ponies. Baird, JD; Ducharme, NG; McCraw, BM; Pennock, P; Slocombe, JO, 1986)	0.85
" Advantages include, the ability to programme the release of compounds to achieve specific effects for various periods, decreasing the frequency of dosage and increasing the choice of compounds for the control of parasitic infections."	( Controlled release technology for the control of helminths in ruminants. Anderson, N, 1985)	0.27
" These three dosage regimes were also associated, respectively, with 92."	( Protection developed against reinfection by Dictyocaulus viviparus following anthelmintic treatment of a one-day-old primary infection in cattle. Oakley, GA, 1981)	0.26
" At therapeutic dosage rates albendazole was 32,5%, thiabendazole 0%, oxfendazole 14,9% and morantel 91,4% effective against the adult stage of Ostertagia spp."	( [Two cases of Ostertagia spp. in sheep showing resistance to benzimidazole anthelmintics]. Geyser, TL; Rezin, VS; Van Schalkwyk, PC, 1983)	0.5
" A comparative bioavailability study of these 3 suspensions was performed in 12 sheep with each sheep given each formulation in a Latin square crossover study design; oxfendazole was dosed at rate of 5 mg/kg of body weight."	( Relationship among particle size distribution, dissolution profile, plasma values, and anthelmintic efficacy of oxfendazole. Hennessey, DR; Mroszczak, E; Nguyen, TH; Parekh, P; Prichard, RK; Schiltz, R; Shastri, S, 1980)	0.67
" This difference was subsequently used to indicate rumen bypass, by oesophageal groove closure, after oral dosing with an OFZ formulation to which glucose had been added."	( Effect of oesophageal groove closure on the pharmacokinetic behaviour and efficacy of oxfendazole in sheep. Hennessy, DR; Prichard, RK, 1981)	0.49
" The assay has been used for statutory testing purposes and for measuring the levels of fenbendazole and oxfendazole in liver and muscle from sheep after dosing with a commercial anthelmintic containing fenbendazole."	( Determination of fenbendazole and oxfendazole in liver and muscle using liquid chromatography-mass spectrometry. Blanchflower, WJ; Cannavan, A; Kennedy, DG, 1994)	0.78
" Where lambs were weaned by removing ewes from the lambing paddock, administration of the CRC at weaning to lambs whose dams had also been treated with the CRC did not result in improved production when compared with lambs from ewes dosed with CRCs and treated after weaning according to the Wormkill program."	( Effects of a controlled-release albendazole capsule on parasitism and production from grazing Merino ewes and lambs. Barger, IA; Rodden, BR; Steel, JW, 1993)	0.29
" The exposure to febantel and its metabolites in fully hydrated camels was significantly higher in camels dosed with febantel paste compared to febantel suspension, as measured by AUC and Cmax."	( The bioavailability of febantel in dehydrated camels. Ben-Zvi, Z; Gussarsky, E; van Creveld, C; Yagil, R, 1996)	0.29
" Group 1 was orally dosed 3 times with increasing numbers of Trichostrongylus colubriformis and Teladorsagia circumcincta infective larvae."	( The results of anthelmintic-abbreviated infections of Trichostrongylus colubriformis and Teladorsagia circumcincta on fecal egg counts in goats on pasture. Hadas, E; Stankiewicz, M, 1997)	0.3
" A controlled dose-response trial was therefore undertaken to determine the efficacy and safety of three concentrations of oxfendazole."	( Treatment of porcine cysticercosis with oxfendazole: a dose-response trial. Bernal, T; Falcon, N; Garcia, HH; Gavidia, C; Gilman, RH; Gonzalez, AE; Romero, M; Tsang, VC, 1997)	0.77
" Calves in the D-group were treated with doramectin pour-on on days 0 and 56, at a dosage of 500 microg kg(-1) BW: calves in the C-group were designated as controls."	( Field evaluation of a topical doramectin formulation for the chemoprophylaxis of parasitic bronchitis in calves. Claerebout, E; Dorny, P; Vercruysse, J; Weatherley, A, 1998)	0.3
" Either 2, 4 or 6 weeks after parturition, groups of ewes were dosed with 24000 L3 of known oxfendazole-resistant parasite strains; 12000 of each species."	( The establishment rate of Ostertagia circumcincta and Trichostrongylus colubriformis in lactating Romney ewes. Brown, AE; Leathwick, DM; Miller, CM; Sutherland, IA, 1999)	0.52
" However, daily dosing at 30 mg of oxfendazole per kg proved highly toxic to sheep, resulting in a 24% death rate in the daily group as compared to a 4 to 6% mortality rate in all other groups."	( Oxfendazole treatment of sheep with naturally acquired hydatid disease. Dueger, EL; Gilman, RH; Moro, PL, 1999)	2.02
"Fifteen naturally parasitised crossbred male ponies were allocated into 3 groups (n = 5) and treated orally as follows: Group I (control) received distilled water as placebo; Group II was dosed with OFZ (10 mg/kg bwt); and Group III was treated with OFZ (10 mg/kg bwt) co-administered with PB (63 mg/kg bwt)."	( Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Alvarez, LI; Fiel, C; Fusé, LA; Lanusse, CE; McKellar, QA; Moreno, L; Sánchez Bruni, SF; Saumell, CA, 2005)	0.72
"This study compared pharmacokinetic (PK) profiles in sheep dosed intravenously with three different concentrations of oxfendazole (OFZ)."	( Effects of formulation concentration on intravenous pharmacokinetics, chirality and in vitro solubility of oxfendazole and its metabolites in sheep. Jones, DG; McKellar, QA; Sánchez Bruni, SF; Small, J, 2005)	0.75
" Further studies have to be performed to transform coacervates into a solid dosage form and to prove broad applicability to other poorly soluble drugs."	( Formulation of poorly water-soluble drugs via coacervation--a pilot study using febantel. Antunes da Fonseca, A; De Geest, BG; De Jaeghere, W; Remon, JP; Van Bocxlaer, J; Vervaet, C, 2013)	0.39
" The model can be used to predict oxfendazole disposition under new dosing regimens to support dose optimization in humans."	( Population Pharmacokinetic Model of Oxfendazole and Metabolites in Healthy Adults following Single Ascending Doses. An, G; Bach, T; Deye, G; Murry, DJ; Stebounova, LV; Winokur, P, 2021)	1.18

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Role	Description
antinematodal drug	A substance used in the treatment or control of nematode infestations.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
sulfoxide	An organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H).
benzimidazoles	An organic heterocyclic compound containing a benzene ring fused to an imidazole ring.
carbamate ester	Any ester of carbamic acid or its N-substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	31.6228	0.0251	20.2376	39.8107	AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	35.4813	0.1778	14.3909	39.8107	AID2147
Luciferase	Photinus pyralis (common eastern firefly)	Potency	2.7540	0.0072	15.7588	89.3584	AID1224835
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	33.8062	0.0060	38.0041	19,952.5996	AID1159521; AID1159523
Fumarate hydratase	Homo sapiens (human)	Potency	22.3872	0.0030	8.7949	48.0869	AID1347053
PPM1D protein	Homo sapiens (human)	Potency	18.5569	0.0052	9.4661	32.9993	AID1347411
TDP1 protein	Homo sapiens (human)	Potency	21.3594	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	8.9026	0.0007	14.5928	83.7951	AID1259369; AID1259392
AR protein	Homo sapiens (human)	Potency	11.7994	0.0002	21.2231	8,912.5098	AID743035; AID743063
caspase 7, apoptosis-related cysteine protease	Homo sapiens (human)	Potency	8.6261	0.0133	26.9810	70.7614	AID1346978
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	37.6505	0.0112	12.4002	100.0000	AID1030
nuclear receptor subfamily 1, group I, member 3	Homo sapiens (human)	Potency	3.0706	0.0010	22.6508	76.6163	AID1224838; AID1224839; AID1224893
EWS/FLI fusion protein	Homo sapiens (human)	Potency	13.8506	0.0013	10.1577	42.8575	AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	10.6822	0.0002	14.3764	60.0339	AID720691
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	2.7275	0.0030	41.6115	22,387.1992	AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	0.7437	0.0008	17.5051	59.3239	AID1159527; AID1159531
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	8.5099	0.0015	30.6073	15,848.9004	AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptor	Homo sapiens (human)	Potency	0.4730	0.3758	27.4851	61.6524	AID743217
pregnane X nuclear receptor	Homo sapiens (human)	Potency	38.4663	0.0054	28.0263	1,258.9301	AID1346982
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	15.7843	0.0002	29.3054	16,493.5996	AID1259244; AID1259248; AID743069; AID743079; AID743080; AID743091
cytochrome P450 2D6	Homo sapiens (human)	Potency	12.3018	0.0010	8.3798	61.1304	AID1645840
polyprotein	Zika virus	Potency	22.3872	0.0030	8.7949	48.0869	AID1347053
peroxisome proliferator-activated receptor delta	Homo sapiens (human)	Potency	8.6980	0.0010	24.5048	61.6448	AID743215
peroxisome proliferator activated receptor gamma	Homo sapiens (human)	Potency	8.6980	0.0010	19.4141	70.9645	AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptor	Homo sapiens (human)	Potency	8.9688	0.0237	23.2282	63.5986	AID743222; AID743223
caspase-3	Homo sapiens (human)	Potency	8.6261	0.0133	26.9810	70.7614	AID1346978
aryl hydrocarbon receptor	Homo sapiens (human)	Potency	3.5931	0.0007	23.0674	1,258.9301	AID743085; AID743122
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	12.0385	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	31.0393	0.0391	47.5451	146.8240	AID1224845
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	35.4813	0.0018	15.6638	39.8107	AID894
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	13.6509	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	16.7842	0.0420	27.3789	61.6448	AID743210
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Voltage-dependent calcium channel gamma-2 subunit	Mus musculus (house mouse)	Potency	21.6679	0.0015	57.7890	15,848.9004	AID1259244
Interferon beta	Homo sapiens (human)	Potency	19.8102	0.0033	9.1582	39.8107	AID1347407; AID1347411
Cellular tumor antigen p53	Homo sapiens (human)	Potency	16.3478	0.0023	19.5956	74.0614	AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Glutamate receptor 2	Rattus norvegicus (Norway rat)	Potency	21.6679	0.0015	51.7393	15,848.9004	AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Hematopoietic prostaglandin D synthase	Homo sapiens (human)	IC50 (µMol)	300.0000	0.0710	0.9222	3.8000	AID442514
Adenosine receptor A2a	Homo sapiens (human)	IC50 (µMol)	1.5040	0.0007	1.5594	10.0000	AID625195
Adenosine receptor A2a	Homo sapiens (human)	Ki	0.8440	0.0000	1.0609	9.7920	AID625195
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
prostaglandin biosynthetic process	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
prostaglandin metabolic process	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
signal transduction	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
locomotory behavior	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
negative regulation of male germ cell proliferation	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
glutathione metabolic process	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
synaptic transmission, dopaminergic	Adenosine receptor A2a	Homo sapiens (human)
response to amphetamine	Adenosine receptor A2a	Homo sapiens (human)
regulation of DNA-templated transcription	Adenosine receptor A2a	Homo sapiens (human)
phagocytosis	Adenosine receptor A2a	Homo sapiens (human)
apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
cellular defense response	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
cell-cell signaling	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, cholinergic	Adenosine receptor A2a	Homo sapiens (human)
central nervous system development	Adenosine receptor A2a	Homo sapiens (human)
blood coagulation	Adenosine receptor A2a	Homo sapiens (human)
sensory perception	Adenosine receptor A2a	Homo sapiens (human)
locomotory behavior	Adenosine receptor A2a	Homo sapiens (human)
blood circulation	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of cell population proliferation	Adenosine receptor A2a	Homo sapiens (human)
response to xenobiotic stimulus	Adenosine receptor A2a	Homo sapiens (human)
response to inorganic substance	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of glutamate secretion	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmission	Adenosine receptor A2a	Homo sapiens (human)
regulation of norepinephrine secretion	Adenosine receptor A2a	Homo sapiens (human)
response to purine-containing compound	Adenosine receptor A2a	Homo sapiens (human)
response to caffeine	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Adenosine receptor A2a	Homo sapiens (human)
synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of urine volume	Adenosine receptor A2a	Homo sapiens (human)
vasodilation	Adenosine receptor A2a	Homo sapiens (human)
eating behavior	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of vascular permeability	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of neuron apoptotic process	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleep	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of alpha-beta T cell activation	Adenosine receptor A2a	Homo sapiens (human)
astrocyte activation	Adenosine receptor A2a	Homo sapiens (human)
neuron projection morphogenesis	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of protein secretion	Adenosine receptor A2a	Homo sapiens (human)
negative regulation of inflammatory response	Adenosine receptor A2a	Homo sapiens (human)
regulation of mitochondrial membrane potential	Adenosine receptor A2a	Homo sapiens (human)
membrane depolarization	Adenosine receptor A2a	Homo sapiens (human)
regulation of calcium ion transport	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of synaptic transmission, glutamatergic	Adenosine receptor A2a	Homo sapiens (human)
excitatory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
inhibitory postsynaptic potential	Adenosine receptor A2a	Homo sapiens (human)
prepulse inhibition	Adenosine receptor A2a	Homo sapiens (human)
apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
presynaptic modulation of chemical synaptic transmission	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Adenosine receptor A2a	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathway	Adenosine receptor A2a	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
magnesium ion binding	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
glutathione transferase activity	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
prostaglandin-D synthase activity	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
calcium ion binding	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
protein binding	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
protein homodimerization activity	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
G protein-coupled adenosine receptor activity	Adenosine receptor A2a	Homo sapiens (human)
protein binding	Adenosine receptor A2a	Homo sapiens (human)
calmodulin binding	Adenosine receptor A2a	Homo sapiens (human)
lipid binding	Adenosine receptor A2a	Homo sapiens (human)
enzyme binding	Adenosine receptor A2a	Homo sapiens (human)
type 5 metabotropic glutamate receptor binding	Adenosine receptor A2a	Homo sapiens (human)
identical protein binding	Adenosine receptor A2a	Homo sapiens (human)
protein-containing complex binding	Adenosine receptor A2a	Homo sapiens (human)
alpha-actinin binding	Adenosine receptor A2a	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
nucleoplasm	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
cytoplasm	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
cytosol	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
intracellular membrane-bounded organelle	Hematopoietic prostaglandin D synthase	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Glutamate receptor 2	Rattus norvegicus (Norway rat)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
intermediate filament	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Adenosine receptor A2a	Homo sapiens (human)
membrane	Adenosine receptor A2a	Homo sapiens (human)
dendrite	Adenosine receptor A2a	Homo sapiens (human)
axolemma	Adenosine receptor A2a	Homo sapiens (human)
asymmetric synapse	Adenosine receptor A2a	Homo sapiens (human)
presynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
neuronal cell body	Adenosine receptor A2a	Homo sapiens (human)
postsynaptic membrane	Adenosine receptor A2a	Homo sapiens (human)
presynaptic active zone	Adenosine receptor A2a	Homo sapiens (human)
glutamatergic synapse	Adenosine receptor A2a	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (80)

Assay ID	Title	Year	Journal	Article
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID147172	Anthelmintic activity against mice, infected with parasite Nematospiroides dubius, at a dose of 31 p.p.m. in feed	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Synthesis and biological activity of a series of diaryl-substituted alpha-cyano-beta-hydroxypropenamides, a new class of anthelmintic agents.
AID679513	TP_TRANSPORTER: transepithelial transport of PhIP (basal to apical) in BCRP-expressing MDCKII cells	2005	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID468443	Inhibition of human FAAH at 1 uM	2009	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 19, Issue:23	Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.
AID442515	Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation at 50 uM	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID147181	Anthelmintic activity ( in Vivo ) in mouse, as percentage reduction of Nematospiroides dubius at 125 PPM	1991	Journal of medicinal chemistry, May, Volume: 34, Issue:5	Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID147167	Anthelmintic activity against mice, infected with parasite Nematospiroides dubius, at a dose of 125 ppm in feed	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Synthesis and biological activity of a series of diaryl-substituted alpha-cyano-beta-hydroxypropenamides, a new class of anthelmintic agents.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID717844	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation at 20 uM after 45 mins by spectrophotometric analysis relative to control	2012	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24	Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
AID147183	Anthelmintic activity ( in Vivo ) in mouse, as percentage reduction of Nematospiroides dubius at 31 PPM	1991	Journal of medicinal chemistry, May, Volume: 34, Issue:5	Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID679782	TP_TRANSPORTER: transepithelial transport (basal to apical) in Bcrp1-expressing MDCKII cells	2005	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID442514	Inhibition of human H-PGDS expressed in Escherichia coli BL21 assessed as rate of glutathione-chloro-dinitro benzene conjugation	2010	European journal of medicinal chemistry, Feb, Volume: 45, Issue:2	Identification and characterisation of new inhibitors for the human hematopoietic prostaglandin D2 synthase.
AID93051	The compound was tested for anthelmintic activity against mice, infected with parasite Hymenolepis nana at a dose of 125 p.p.m. in feed	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Synthesis and biological activity of a series of diaryl-substituted alpha-cyano-beta-hydroxypropenamides, a new class of anthelmintic agents.
AID93172	The compound was tested for anthelmintic activity against mice, infected with parasite Hymenolepis nana at a dose of 31 p.p.m. in feed	1991	Journal of medicinal chemistry, Nov, Volume: 34, Issue:11	Synthesis and biological activity of a series of diaryl-substituted alpha-cyano-beta-hydroxypropenamides, a new class of anthelmintic agents.
AID147185	Anthelmintic activity ( in Vivo ) in mouse, as percentage reduction of Nematospiroides dubius at 62 PPM	1991	Journal of medicinal chemistry, May, Volume: 34, Issue:5	Synthesis and anthelmintic activity of 3'-benzoylurea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole.
AID679679	TP_TRANSPORTER: transepithelial transport of PhIP (basal to apical) in Bcrp1-expressing MDCKII cells	2005	Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 33, Issue:5	Transport of anthelmintic benzimidazole drugs by breast cancer resistance protein (BCRP/ABCG2).
AID1347126	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347141	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347117	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347139	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347138	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D caspase screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347123	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347140	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347135	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347136	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347110	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347137	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Orthogonal 3D viability screen for Daoy cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	136 (39.42)	18.7374
1990's	97 (28.12)	18.2507
2000's	45 (13.04)	29.6817
2010's	47 (13.62)	24.3611
2020's	20 (5.80)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	45 (12.47%)	5.53%
Reviews	6 (1.66%)	6.00%
Case Studies	3 (0.83%)	4.05%
Observational	0 (0.00%)	0.25%
Other	307 (85.04%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 2, Partially-Blinded, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to a Single Dose of Albendazole for the Treatment of Trichuris Trichiura Infection in Adults [NCT04713787]	Phase 2	249 participants (Anticipated)	Interventional	2023-10-01	Not yet recruiting
An Open Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults [NCT02636803]	Phase 2	0 participants (Actual)	Interventional	2019-11-30	Withdrawn(stopped due to not going to be conducted)
A Phase 1, Bioavailability Study to Investigate the Pharmacokinetics, Safety and Tolerability of an Oxfendazole Tablet Formulation in a Randomized, Double-Blind, Placebo-Controlled Design After Single and Multiple Oral Dosing in Healthy Adult Volunteers [NCT04920292]	Phase 1	30 participants (Actual)	Interventional	2022-04-21	Completed
A Randomized, Double-Blind Placebo-Controlled Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole [NCT02234570]	Phase 1	70 participants (Actual)	Interventional	2014-11-17	Completed
A Phase 1 Open Label, Multiple Ascending Dose Study of Oxfendazole in Healthy Adult Volunteers [NCT03035760]	Phase 1	36 participants (Actual)	Interventional	2017-05-12	Completed
An Assessor Blind, Randomized, Comparative Study of the Efficacy of Different Doses of Oxfendazole Compared to Single Dose Albendazole in the Treatment of Trichuris Trichiura Infection in Adults [NCT03435718]	Phase 2	250 participants (Anticipated)	Interventional	2024-07-31	Not yet recruiting
Phase I Study of Oxfendazole (Toward the Treatment of Neurocysticercosis) [NCT01584362]	Phase 1	0 participants (Actual)	Interventional	2016-08-31	Withdrawn(stopped due to study conducted under Clinical Trials Agreement as NIAID registration NCT02234570)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT02234570 (9) [back to overview]	Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0-infinity)) for Oxfendazole
NCT02234570 (9) [back to overview]	Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma
NCT02234570 (9) [back to overview]	Number of Subjects Reporting Adverse Events Related to Oxfendazole Within 14 Days of Receipt of a Single Oral Dose.
NCT02234570 (9) [back to overview]	Terminal Elimination Half-life (t1/2) of Oxfendazole
NCT02234570 (9) [back to overview]	Time of Maximum Observed Concentration (Tmax) of Oxfendazole
NCT02234570 (9) [back to overview]	Plasma Concentrations of Oxfendazole Fenbendazole
NCT02234570 (9) [back to overview]	Plasma Concentrations of Oxfendazole Sulfone
NCT02234570 (9) [back to overview]	Urine Concentrations of Oxfendazole Fenbendazole
NCT02234570 (9) [back to overview]	Urine Concentrations of Oxfendazole Sulfone
NCT03035760 (10) [back to overview]	Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arm 4
NCT03035760 (10) [back to overview]	Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3
NCT03035760 (10) [back to overview]	Area Under the Concentration Time-curve for a Single Dosing Interval (AUCtau) of Oxfendazole for Arm 1, 2 and 3
NCT03035760 (10) [back to overview]	Area Under the Concentration Time-curve to the Time of Last Measured Concentration (AUClast) of Oxfendazole for Arm 4
NCT03035760 (10) [back to overview]	Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arm 4
NCT03035760 (10) [back to overview]	Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arms 1, 2, and 3
NCT03035760 (10) [back to overview]	Terminal Elimination Half-life (t1/2) of Oxfendazole for Arm 4
NCT03035760 (10) [back to overview]	Terminal Elimination Half-life (t1/2) of Oxfendazole for Arms 1, 2, and 3
NCT03035760 (10) [back to overview]	Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arm 4
NCT03035760 (10) [back to overview]	Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arms 1, 2, and 3

Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0-infinity)) for Oxfendazole

AUC(0-infinity) was defined as the total area under the concentration-time curve from dosing (time 0) taken to the limit as the end time becomes arbitrarily large. AUC(0-infinity) and was calculated by adding AUC(0-last) to an extrapolated value equal to the last measured concentration greater than the lower limit of quantification of the bioanalytical assay divided by the terminal phase elimination rate constant (Ke) computed from concentrations that were measured using a validated HPLCMS/MS method (NCT02234570)
Timeframe: 0, 1, 2, 4, 6, 8, 10, 12, 24, 48, 72, 120, 168, 336 hours post-dose

Intervention	ng•hr/mL (Geometric Mean)
0.5 mg/kg Oxfendazole	11682.4
1 mg/kg Oxfendazole	13117.7
3 mg/kg Oxfendazole	30803.1
7.5 mg/kg Oxfendazole	73928.9
15 mg/kg Oxfendazole	99542.6
30 mg/kg Oxfendazole	78344.0
60 mg/kg Oxfendazole	108618.2

Intervention	ng/mL (Geometric Mean)
0.5 mg/kg Oxfendazole	943.9
1 mg/kg Oxfendazole	1155.9
3 mg/kg Oxfendazole	2436.9
7.5 mg/kg Oxfendazole	4781.3
15 mg/kg Oxfendazole	6254.8
30 mg/kg Oxfendazole	5301.3
60 mg/kg Oxfendazole	6768.4

Intervention	ng/mL (Mean)
	1 Hour	2 Hours	4 Hours	6 Hours	8 Hours	10 Hours	12 Hours	24 Hours	Day 3	Day 4	Day 6	Day 8	Day 15
0.5 mg/kg Oxfendazole	0	0	0.6	0.5	0.3	0.3	0.3	0.7	0.4	0.4	0.4	0.4	0.4
1 mg/kg Oxfendazole	0	0	0.8	2.0	1.9	2.3	2.3	2.3	0.9	0.9	0.9	0.9	0.9
15 mg/kg Oxfendazole	1.0	2.6	8.1	9.9	10.8	11.2	11.7	10.0	3.7	1.2	1.0	1.0	1.0
3 mg/kg Oxfendazole	0.3	0.4	3.5	4.8	5.2	6.8	6.7	7.1	3.2	1.1	1.0	1.0	1.0
30 mg/kg Oxfendazole	1.4	2.2	4.4	5.8	5.0	5.5	6.4	5.4	2.5	1.3	0.9	0.9	0.9
60 mg/kg Oxfendazole	5.9	6.3	8.0	12.4	15.5	18.4	20.9	16.7	5.5	2.5	1.7	1.0	1.0
7.5 mg/kg Oxfendazole	0.3	1.1	3.0	6.6	6.7	10.0	10.1	4.9	2.2	1.4	1.0	1.0	1.0

Intervention	ng/mL (Mean)
	0-4 hours	4-8 hours	8-12 hours	12-24 hours	24-32 hours	48-60 hours
0.5 mg/kg Oxfendazole	0	0	0	0	0	0
1 mg/kg Oxfendazole	0	0	0	0	0	0
15 mg/kg Oxfendazole	0	0	0	0	0	0
3 mg/kg Oxfendazole	0	0	0	0	0	0
30 mg/kg Oxfendazole	0	0	0	0	0	0
60 mg/kg Oxfendazole	0	0	0	0	0.03	0
7.5 mg/kg Oxfendazole	0	0	0	0	0	0.28

Intervention	Participants (Count of Participants)
Arm 4: 3 mg/kg Oxfendazole, Post Fast	1
Arm 4: 3 mg/kg Oxfendazole, Post Fed	2

Intervention	Participants (Count of Participants)
Arm 1: 3 mg/kg Oxfendazole for 5 Days	3
Arm 2: 7.5 mg/kg Oxfendazole for 5 Days	3
Arm 3: 15 mg/kg Oxfendazole for 5 Days	1

Intervention	ng•hr/mL (Geometric Mean)
	Dose 1	Dose 5
Arm 1: 3 mg/kg Oxfendazole for 5 Days	30200	38200
Arm 2: 7.5 mg/kg Oxfendazole for 5 Days	52500	65700
Arm 3: 15 mg/kg Oxfendazole for 5 Days	71800	69600

Condition	Indicated	Relationship Strength	Studies	Trials
Infections, Nematode [description not available]	0	8.56	57	8
Encephalitis, Polio [description not available]	0	2.06	1	0
Poliomyelitis An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)	0	2.06	1	0
Benign Neoplasms [description not available]	0	3.03	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	3.03	1	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.56	8	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	5.08	10	1
Equine Diseases [description not available]	0	5.93	14	2
Ovine Diseases [description not available]	0	9.44	80	14
Caprine Diseases [description not available]	0	5.81	12	2
Haemonchiasis Infection with nematodes of the genus HAEMONCHUS, characterized by digestive abnormalities and anemia similar to that from hookworm infestation.	0	6.78	34	2
Central Nervous System Cysticercosis [description not available]	0	4.63	5	0
Neurocysticercosis Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50)	0	9.63	5	0
Carcinoma, Non-Small Cell Lung [description not available]	0	2.72	2	0
Cancer of Lung [description not available]	0	2.72	2	0
Cancer of Ovary [description not available]	0	2.6	1	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	0	2.72	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	0	2.72	2	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	0	2.6	1	0
Bancroftian Elephantiasis [description not available]	0	2.25	1	0
Elephantiasis, Filarial Parasitic infestation of the human lymphatic system by WUCHERERIA BANCROFTI or BRUGIA MALAYI. It is also called lymphatic filariasis.	0	2.25	1	0
Onchocerciasis Infection with nematodes of the genus ONCHOCERCA. Characteristics include the presence of firm subcutaneous nodules filled with adult worms, PRURITUS, and ocular lesions.	0	3.2	5	0
Swine Diseases Diseases of domestic swine and of the wild boar of the genus Sus.	0	11.35	29	11
Infections, Taenia [description not available]	0	6.29	7	2
Taeniasis Infection with tapeworms of the genus Taenia.	1	8.29	7	2
Coenuri Infection [description not available]	0	9.08	18	7
Cysticercosis Infection with CYSTICERCUS, the larval form of the various tapeworms of the genus Taenia (usually T. solium in man). In humans they penetrate the intestinal wall and invade subcutaneous tissue, brain, eye, muscle, heart, liver, lung, and peritoneum. Brain involvement results in NEUROCYSTICERCOSIS.	1	11.08	18	7
African Swine Fever A sometimes fatal ASFIVIRUS infection of pigs, characterized by fever, cough, diarrhea, hemorrhagic lymph nodes, and edema of the gallbladder. It is transmitted between domestic swine by direct contact, ingestion of infected meat, or fomites, or mechanically by biting flies or soft ticks (genus Ornithodoros).	0	7.17	1	0
Intestinal Diseases, Parasitic Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS.	0	6.49	25	2
Trichocephaliasis [description not available]	0	2.4	2	0
Trichuriasis Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus.	1	4.4	2	0
Canine Diseases [description not available]	0	4.76	7	1
Eye Disorders [description not available]	0	2.17	1	0
Eye Diseases Diseases affecting the eye.	0	2.17	1	0
Infections, Nematomorpha [description not available]	0	6.61	12	1
Zoonoses Diseases of non-human animals that may be transmitted to HUMANS or may be transmitted from humans to non-human animals.	0	3.12	1	0
Helminthiasis, Animal Infestation of animals with parasitic worms of the helminth class. The infestation may be experimental or veterinary.	0	7.39	15	2
Helminthiasis Infestation with parasitic worms of the helminth class.	1	8.61	12	1
Ascariasis Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer.	0	2.89	4	0
Adverse Drug Event [description not available]	0	3.47	1	1
Parasitic Diseases, Animal Animal diseases caused by PARASITES.	0	5.54	6	3
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	3.47	1	1
Bovine Diseases [description not available]	0	8.26	66	5
Cholera Infantum [description not available]	0	4.3	4	1
Experimental Hepatoma [description not available]	0	3.12	5	0
Cyst, Pulmonary Hydatid [description not available]	0	3.83	2	1
Alveolar Echinococcosis, Hepatic [description not available]	0	3.43	1	1
Fasciola Infection [description not available]	0	4.69	3	2
Fascioliasis Liver disease caused by infections with parasitic flukes of the genus FASCIOLA, such as FASCIOLA HEPATICA.	0	4.69	3	2
Cystic Echinococcosis [description not available]	0	10.2	6	2
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	0	2.05	1	0
Adenoma, Hepatocellular [description not available]	0	2.06	1	0
Condition, Preneoplastic [description not available]	0	2.06	1	0
Cocarcinogenesis The combination of two or more different factors in the production of cancer.	0	2.42	2	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	0	2.06	1	0
Ostertagiasis A disease of herbivorous mammals, particularly cattle and sheep, caused by stomach worms of the genus OSTERTAGIA.	0	7.63	43	4
Monieziasis Infection of ruminants with tapeworms of the genus Moniezia.	0	3.79	2	1
Trichostrongyloidiasis Infection by roundworms of the superfamily TRICHOSTRONGYLOIDEA, including the genera TRICHOSTRONGYLUS; OSTERTAGIA; Cooperia, HAEMONCHUS; Nematodirus, Hyostrongylus, and DICTYOCAULUS.	0	7.04	45	2
Weight Gain Increase in BODY WEIGHT over existing weight.	0	9.87	8	1
Brain Disorders [description not available]	0	2.03	1	0
Bertielliasis [description not available]	0	4.05	3	1
Brain Diseases Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM.	0	2.03	1	0
Infections, Oxyurida [description not available]	0	3.42	1	1
Eosinophilia, Tropical [description not available]	0	2.39	2	0
Cardiac Diseases [description not available]	0	2.03	1	0
Eosinophilia Abnormal increase of EOSINOPHILS in the blood, tissues or organs.	0	2.39	2	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	0	2.03	1	0
Glossitis Inflammation of the tongue.	0	2.03	1	0
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	0	1.96	1	0
Angiostrongylus Infections [description not available]	0	2.38	2	0
Dictyocauliasis [description not available]	0	5.8	22	1
Aspiculariasis [description not available]	0	2.65	3	0
Equine Strongyle Infections [description not available]	0	5.92	14	2
Habronemiasis [description not available]	0	1.96	1	0
Human Trichinellosis [description not available]	0	3.06	5	0
Trichinellosis An infection with TRICHINELLA. It is caused by eating raw or undercooked meat that is infected with larvae of nematode worms TRICHINELLA genus. All members of the TRICHINELLA genus can infect human in addition to TRICHINELLA SPIRALIS, the traditional etiological agent. It is distributed throughout much of the world and is re-emerging in some parts as a public health hazard and a food safety problem.	0	3.06	5	0
Ancylostomiasis Infection of humans or animals with hookworms of the genus ANCYLOSTOMA. Characteristics include anemia, dyspepsia, eosinophilia, and abdominal swelling.	0	2.37	2	0
Parasite Infections [description not available]	0	4.04	3	1
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	0	3.35	7	0
Trichostrongylosis Infestation with nematode worms of the genus TRICHOSTRONGYLUS. Man and animals become infected by swallowing larvae, usually with contaminated food or drink, although the larvae may penetrate human skin.	0	6.52	26	2
Oesophagostomiasis Infection of the intestinal tract with worms of the genus OESOPHAGOSTOMUM. This condition occurs mainly in animals other than man.	0	2.88	4	0
Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment.	0	1.96	1	0
Bunostomiasis [description not available]	0	2.36	2	0
Hookworm Infections Infection of humans or animals with hookworms other than those caused by the genus Ancylostoma or Necator, for which the specific terms ANCYLOSTOMIASIS and NECATORIASIS are available.	0	2.36	2	0
Aging The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.	0	3.37	1	1
Lung Diseases, Parasitic Infections of the lungs with parasites, most commonly by parasitic worms (HELMINTHS).	0	4.28	4	1
Dehydration The condition that results from excessive loss of water from a living organism.	0	1.99	1	0
Fasciolopsiasis [description not available]	0	1.99	1	0
Diathesis [description not available]	0	3.38	1	1
Elaeophoriasis [description not available]	0	1.98	1	0
Filariasis Infections with nematodes of the superfamily FILARIOIDEA. The presence of living worms in the body is mainly asymptomatic but the death of adult worms leads to granulomatous inflammation and permanent fibrosis. Organisms of the genus Elaeophora infect wild elk and domestic sheep causing ischemic necrosis of the brain, blindness, and dermatosis of the face.	1	3.98	1	0
Gastroenteritis INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER.	0	3.47	8	0
Bronchitis Inflammation of the large airways in the lung including any part of the BRONCHI, from the PRIMARY BRONCHI to the TERTIARY BRONCHI.	0	3.47	8	0
Giardia duodenalis Infection [description not available]	0	3.39	1	1
Giardiasis An infection of the SMALL INTESTINE caused by the flagellated protozoan GIARDIA. It is spread via contaminated food and water and by direct person-to-person contact.	0	3.39	1	1
Gastric Diseases [description not available]	0	1.95	1	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	1.98	1	0
Toxocariasis Infection by round worms of the genus TOXOCARA, usually found in wild and domesticated cats and dogs and foxes, except for the larvae, which may produce visceral and ocular larva migrans in man.	0	1.97	1	0
Complications, Infectious Pregnancy [description not available]	0	2.37	2	0

Intervention	ng/mL (Mean)
	1 Hour	2 Hours	4 Hours	6 Hours	8 Hours	10 Hours	12 Hours	24 Hours	Day 3	Day 4	Day 6	Day 8	Day 15
0.5 mg/kg Oxfendazole	28.5	48.7	52.3	57.3	59.7	62.8	56.8	30.9	11.4	3.6	1.2	1.0	1.0
1 mg/kg Oxfendazole	31.1	56.0	67.6	75.1	78.2	70.7	65.4	38.9	11.1	2.8	1.3	1.0	1.0
15 mg/kg Oxfendazole	111.6	219.2	258.6	308.3	336.8	340.8	359.3	261.8	75.1	16.7	1.2	1.0	1.0
3 mg/kg Oxfendazole	73.0	106.3	108.1	113.8	135.5	119.4	111.4	68.5	20.8	5.7	1.3	1.0	1.0
30 mg/kg Oxfendazole	161.5	262.6	285.7	330.3	356.3	352.4	343.7	185.2	57.5	17.2	4.0	1.0	1.0
60 mg/kg Oxfendazole	209.1	319.0	345.4	404.6	454.8	470.7	487.7	362.2	119.5	33.8	6.6	1.1	1.0
7.5 mg/kg Oxfendazole	100.5	182.3	223.8	264.1	296.2	308.7	296.0	176.7	64.8	17.3	6.4	1.0	1.0

oxfendazole

Cross-References

Synonyms (157)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (1)

Drug Classes (3)

Protein Targets (56)

Potency Measurements

Inhibition Measurements

Biological Processes (204)

Molecular Functions (49)

Ceullar Components (33)

Bioassays (80)

Research

Studies (345)

Market Indicators

Research Demand Index: 46.83

Study Types

Clinical Trials (7)

Trial Overview

Trial Outcomes

Area Under the Concentration Time-curve From Time Zero to Infinity (AUC(0-infinity)) for Oxfendazole

Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma

Number of Subjects Reporting Adverse Events Related to Oxfendazole Within 14 Days of Receipt of a Single Oral Dose.

Terminal Elimination Half-life (t1/2) of Oxfendazole

Time of Maximum Observed Concentration (Tmax) of Oxfendazole

Plasma Concentrations of Oxfendazole Fenbendazole

Plasma Concentrations of Oxfendazole Sulfone

Urine Concentrations of Oxfendazole Fenbendazole

Urine Concentrations of Oxfendazole Sulfone

Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arm 4

Number of Subjects Reporting Adverse Events (AEs) Related to Oxfendazole for Arms 1, 2, and 3

Area Under the Concentration Time-curve for a Single Dosing Interval (AUCtau) of Oxfendazole for Arm 1, 2 and 3

Area Under the Concentration Time-curve to the Time of Last Measured Concentration (AUClast) of Oxfendazole for Arm 4

Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arm 4

Maximum Observed Concentration (Cmax) of Oxfendazole in Plasma for Arms 1, 2, and 3

Terminal Elimination Half-life (t1/2) of Oxfendazole for Arm 4

Terminal Elimination Half-life (t1/2) of Oxfendazole for Arms 1, 2, and 3

Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arm 4

Time of Maximum Observed Concentration (Tmax) of Oxfendazole for Arms 1, 2, and 3

Related Drugs (247)

Related Conditions (101)